MBGPF (Moberg Pharma AB) Cash-to-Debt : 84.37 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Moberg Pharma AB's cash to debt ratio for the quarter that ended in Sep. 2024 was 84.37.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Moberg Pharma AB could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Moberg Pharma AB's Cash-to-Debt or its related term are showing as below:

MBGPF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 2.92 Max: 84.26
Current: 84.26

During the past 13 years, Moberg Pharma AB's highest Cash to Debt Ratio was 84.26. The lowest was 0.06. And the median was 2.92.

MBGPF's Cash-to-Debt is ranked better than
87.95% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs MBGPF: 84.26

Moberg Pharma AB Cash-to-Debt Historical Data

The historical data trend for Moberg Pharma AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Moberg Pharma AB Cash-to-Debt Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.19

N/A

25.91

20.46

12.63

Moberg Pharma AB Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															26.78	12.63	8.73	81.58	84.37

Competitive Comparison of Moberg Pharma AB's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Cash-to-Debt falls into.

Moberg Pharma AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Moberg Pharma AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.835	/	(0.124	+	0.338)
	=	12.63

Moberg Pharma AB's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	30.205	/	(0.127	+	0.231)
	=	84.37

Moberg Pharma AB (OTCPK:MBGPF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Moberg Pharma AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MOB:Sweden MOBs:UK MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.